Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013

Researchers identify mechanism implicated in brain cancer and drug that decreases brain tumor growth

Researchers at the University of Calgary's Hotchkiss Brain Institute (HBI) have made a discovery that could lead to better treatment for patients suffering from brain cancer.

9 Dec 2013

PKM2 protein controls mitosis, saving cancer cells from death and promoting brain tumor growth

Researchers have caught a protein they previously implicated in a variety of cancer-promoting roles performing a vital function in cell division, survival and development of brain tumors.

8 Dec 2013

Study uncovers novel mechanism by which glioblastoma evades targeted therapies

A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma, the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in cancer.

6 Dec 2013

Researchers discover biological mechanism that allows brain tumor cells to escape from drugs

Researchers from UCLA's Jonsson Comprehensive Cancer Center have discovered a biological mechanism that allows brain tumor cells to escape from the drugs designed to target them, resulting in drug resistance. The study was published in the December 5, 2013 online issue of Science.

6 Dec 2013

Study reveals that brain cancer cells resist therapy by dialing down gene mutation targeted by drugs

A team of scientists, led by principal investigator Paul S. Mischel, MD, a member of the Ludwig Institute for Cancer Research and professor in the Department of Pathology at the University of California, San Diego School of Medicine, has found that brain cancer cells resist therapy by dialing down the gene mutation targeted by drugs, then re-amplify that growth-promoting mutation after therapy has stopped.

6 Dec 2013

Researchers identify new form of treatment for brain tumor

Glioblastoma is one of the most ominous brain tumors. Despite aggressive surgery, radiation and chemotherapy the outcome of this disease is almost always fatal.

26 Nov 2013

Cocktail eradicates animals' brain tumors

A novel immune-boosting drug combination eradicates brain cancer in mice, according to a study in The Journal of Experimental Medicine.

26 Nov 2013

Phase 1/2 clinical trial data for VAL-083 in glioblastoma is presented at 18th Annual SNO meeting

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting in San Francisco.

25 Nov 2013

Researchers create new statistical tools to find clues about cancer from raw data

Researchers at Rice University, Baylor College of Medicine (BCM) and the University of Texas at Austin are working together to create new statistical tools that can find clues about cancer that are hidden like needles in enormous haystacks of raw data.

15 Nov 2013

Polymer for mending broken bones holds hope for delivering chemotherapy drugs to the brain

A polymer originally designed to help mend broken bones could be successful in delivering chemotherapy drugs directly to the brains of patients suffering from brain tumours, researchers at The University of Nottingham have discovered.

14 Nov 2013

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

As of September 30, 2013, Delmar Pharmaceuticals has cash and equivalents of approximately $5.2 million and its working capital balance is in line with its expectations.

11 Nov 2013

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

TGen-led study reveals viable target to prevent spread of brain cancer

A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, according to a study led by the Translational Genomics Research Institute.

11 Nov 2013

Cytrx announces Q3 2013 financial results, provides clinical update

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three and nine-month periods ended September 30, 2013, and provided a clinical update.

29 Oct 2013

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

Aduro BioTech, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for CRS-207, a novel immunotherapy, for the treatment of pancreatic cancer.

22 Oct 2013

Angiochem initiates ANG1005 Phase 2 study in patients with recurrent high-grade glioma

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in patients with recurrent high-grade glioma.

22 Oct 2013

Study opens doors to novel treatments for aggressive brain cancer

Ludwig researchers have elucidated a key mechanism by which cancer cells change how they metabolize glucose to generate the energy and raw materials required to sustain runaway growth.

22 Oct 2013

New investigational drug offers potential treatment option for lung cancer

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

21 Oct 2013

Research delves deeply into genomics of glioblastoma multiforme cases to better target disease

When The Cancer Genome Atlas launched its massively collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first.

11 Oct 2013

Glioblastoma News and Research

Further Reading

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

Researchers identify mechanism implicated in brain cancer and drug that decreases brain tumor growth

PKM2 protein controls mitosis, saving cancer cells from death and promoting brain tumor growth

Study uncovers novel mechanism by which glioblastoma evades targeted therapies

Researchers discover biological mechanism that allows brain tumor cells to escape from drugs

Study reveals that brain cancer cells resist therapy by dialing down gene mutation targeted by drugs

Researchers identify new form of treatment for brain tumor

Cocktail eradicates animals' brain tumors

Phase 1/2 clinical trial data for VAL-083 in glioblastoma is presented at 18th Annual SNO meeting

Researchers create new statistical tools to find clues about cancer from raw data

Polymer for mending broken bones holds hope for delivering chemotherapy drugs to the brain

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

TGen-led study reveals viable target to prevent spread of brain cancer

Cytrx announces Q3 2013 financial results, provides clinical update

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

Angiochem initiates ANG1005 Phase 2 study in patients with recurrent high-grade glioma

Study opens doors to novel treatments for aggressive brain cancer

New investigational drug offers potential treatment option for lung cancer

Research delves deeply into genomics of glioblastoma multiforme cases to better target disease

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News